P
Peter N. Morcos
Researcher at Hoffmann-La Roche
Publications - 77
Citations - 4660
Peter N. Morcos is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Alectinib & Crizotinib. The author has an hindex of 20, co-authored 72 publications receiving 3570 citations. Previous affiliations of Peter N. Morcos include Genentech & La Roche College.
Papers
More filters
Journal ArticleDOI
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Solange Peters,D. Ross Camidge,Alice T. Shaw,Shirish M. Gadgeel,Jin S. Ahn,Dong Wan Kim,Sai-Hong Ignatius Ou,Maurice Perol,Rafal Dziadziuszko,Rafael Rosell,Ali Zeaiter,Emmanuel Mitry,Sophie Golding,Bogdana Balas,Johannes Noe,Peter N. Morcos,Tony Mok +16 more
TL;DR: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK‐positive NSCLC and independent review committee–assessed progression‐free survival were consistent with those for the primary end point.
Journal ArticleDOI
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel,Leena Gandhi,Gregory J. Riely,Alberto Chiappori,Howard West,Michele C. Azada,Peter N. Morcos,Ruey Min Lee,Linta Garcia,Li Yu,Frederic Boisserie,Laura Di Laurenzio,Sophie Golding,Jotaro Sato,Shumpei Yokoyama,Tomohiro Tanaka,Sai-Hong Ignatius Ou +16 more
TL;DR: Alectinib was well tolerated, with promising antitumour activity in patients with ALK-rearranged NSCLC resistant to crizotinib, including those with CNS metastases.
Journal ArticleDOI
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study
Sai-Hong Ignatius Ou,Jin Seok Ahn,Luigi De Petris,Ramaswamy Govindan,James Chih-Hsin Yang,Brett G.M. Hughes,Hervé Lena,Denis Moro-Sibilot,Alessandra Bearz,Santiago Viteri Ramirez,Tarek Mekhail,Alexander I. Spira,Walter Bordogna,Bogdana Balas,Peter N. Morcos,Annabelle Monnet,Ali Zeaiter,Dong Wan Kim +17 more
TL;DR: Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory ALK-positive NSCLC, including those with CNS metastases, and the cumulative CNS progression rate was lower than the cumulative non-CNS progression rate at 12 months for all patients.
Journal ArticleDOI
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
Edward Gane,Stuart K. Roberts,Catherine A.M. Stedman,Peter W Angus,Brett Ritchie,Rob Elston,David Ipe,Peter N. Morcos,Linda Baher,Isabel Najera,Tom Chu,Uri Lopatin,M.M. Berrey,William Bradford,Mark Laughlin,Nancy S. Shulman,Patrick F. Smith +16 more
TL;DR: The combination of RG7128 and danoprevir was well tolerated with no treatment-related serious or severe adverse events, no grade 3 or 4 changes in laboratory parameters, and no safety-related treatment discontinuations.
Journal ArticleDOI
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Martin Hutchings,Franck Morschhauser,Gloria Iacoboni,Carmelo Carlo-Stella,Fritz Offner,Anna Sureda,Gilles Salles,Joaquin Martinez-Lopez,Michael Crump,Denise Thomas,Peter N. Morcos,Cristiano Ferlini,Ann-Marie E Bröske,Anton Belousov,Marina Bacac,Natalie Dimier,David Carlile,Linda Lundberg,David Perez-Callejo,Pablo Umana,Tom Moore,Martin Weisser,Michael Dickinson +22 more
TL;DR: PURPOSEGlofitamab as mentioned in this paper is a bispecific antibody possessing a 2:1 structure with bivalency for B cells and monovalency for CD3 on T cells.